Researchers from Rowan-Virtua School of Osteopathic Medicine (Rowan-Virtua SOM) and Durin Technologies have reported data from a blood test for Alzheimer’s disease (AD).

The newly designed blood test uses eight autoantibody biomarkers to identify the presence of pathology related to AD up to ten years before symptoms emerge and with an accuracy rate of around 97%.

For the study, the researchers collected blood samples from 328 people to determine if a test that monitors a small number of a patient’s autoantibodies can detect AD-related pathology when the disease is in the pre-symptomatic, prodromal or mild-moderate stages.

The samples for the trial were obtained from participants enrolled in trials at the Alzheimer’s Disease Neuroimaging Initiative, the New Jersey Institute for Successful Aging and the Parkinson’s Study Group.

Samples collected from 106 healthy, non-demented individuals served as controls.

Durin Technologies founder and chief scientific officer and Rowan-Virtua SOM Geriatrics and Gerontology professor Dr Robert Nagele said: “Alzheimer’s disease pathology begins a decade or more before the emergence of hallmark symptoms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“An accurate, non-invasive blood test for early detection and monitoring of AD could bend the curve of clinical outcomes through earlier participation in clinical trials and monitoring of AD progression of patients under treatment.”

The blood test is expected to identify the presence of AD pathology across the disease’s progression, including among those originally determined to have no signs.

The minimally invasive and inexpensive test can diagnose or predict a clinical decline in individuals who are asymptomatic.

It can also monitor the progress of patients undergoing treatment and is suitable for use in clinical trials as well as frontline and community primary care settings, including those in economically disadvantaged and rural regions.